Understanding Lesion Progression in a Chronic Model of Cerebral Cavernous Malformations through Combined MRI and Histology
Delaney G. FisheriD, Khadijeh Alsadat SharifiiD, Emine Zeynep UlutasiD, Jeyan Sathia KumariD, M. Yashar S. KalaniiD, G. Wilson MilleriD, Richard J. PriceiD, Petr TvrdíkiD
Abstract
Cerebral cavernous malformations (CCM), also known as cavernous angiomas, are blood vessel abnormalities comprised of clusters of grossly enlarged and hemorrhage-prone capillaries. The prevalence in the general population, including asymptomatic cases, is estimated to be 0.5%. Some patients develop severe symptoms, including seizures and focal neurologic deficits, while others have no symptoms. The causes of this remarkable presentation heterogeneity within a primarily monogenic disease remain poorly understood. To address this problem, we have established a chronic mouse model of CCM, induced by postnatal ablation of Krit1 with Pdgfb-CreERT. These mice develop CCM lesions gradually over 4-6 months of age throughout of the brain. We examined lesion progression in these mice with T2-weighted 7T MRI protocols. Precise volumetric analysis of individual lesions revealed non-monotonous behavior, with some lesions temporarily growing smaller. However, the cumulative lesional volume invariably increased over time and accelerated after about 3 months. Next, we established a modified protocol for dynamic contrast enhanced (DCE) MR imaging and produced quantitative maps of gadolinium tracer MultiHance in the lesions, indicating a high degree of heterogeneity in lesional permeability. Multivariate comparisons of MRI properties of the lesions with cellular markers for endothelial cells, astrocytes, and microglia revealed that increased cell density surrounding lesions correlates with stability, while increased vasculature within and surrounding lesions may correlate with instability. Our results lay a foundation for better understanding individual lesion properties and provide a comprehensive pre-clinical platform for testing new drug and gene therapies for controlling CCM.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 1
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Novel hemorrhage models of cerebral cavernous malformations
Matthew R. Detter, Robert Shenkar, … Douglas A. Marchuk·bioRxiv·Feb 12, 2020
- Cerebral Cavernous Malformations Develop through Clonal Expansion of Mutant Endothelial Cells
Matthew R. Detter, Daniel A. Snellings, Douglas A. Marchuk·Circulation ResearchPeer-reviewed·Oct 25, 2018
- Non cell-autonomous effect of astrocytes on cerebral cavernous malformations
Miguel Alejandro Lopez‐Ramirez, Shady Ibrahim Soliman, … Mark H. Ginsberg·bioRxiv·Jan 29, 2021
- Hyaluronic acid turnover controls the severity of Cerebral Cavernous Malformations in bioengineered human micro-vessels
T. E. Yordanov, M. A. E. Martinez, … A. K. Lagendijk·bioRxiv·Mar 27, 2023
- Behavioral impairments are linked to neuroinflammation in mice with Cerebral Cavernous Malformation disease
Joseph Offenberger, Bianca Chen, … Miguel Alejandro Lopez‐Ramirez·bioRxiv·May 29, 2024
- Neuroinflammation plays a critical role in cerebral cavernous malformation disease
Catherine Chinhchu Lai, Bliss Nelsen, … Miguel Alejandro Lopez‐Ramirez·Circulation ResearchPeer-reviewed·Oct 26, 2022